FROM BASEMENT MEMBRANE DEFECTS TO PRECISION MEDICINE: ADVANCES IN ALPORT SYNDROME
Abstract
Alport syndrome is a hereditary disorder characterized by progressive renal dysfunction, sensorineural hearing loss, and ocular abnormalities, resulting from mutations in COL4A3, COL4A4, COL4A5. The clinical phenotype ranges from isolated hematuria to early-onset end-stage renal disease, with variability determined by inheritance patterns and specific genotypes. Diagnosis relies on combination of clinical assessment, renal biopsy with electron microscopy, and targeted genetic testing, enabling precise characterization of disease severity and informing management strategies. Current therapeutic approaches focus on renoprotective interventions, primarily angiotensin-converting enzyme inhibitors and angiotensin receptor blockers, with emerging evidence supporting adjunctive use of sodium-glucose cotransporter 2 inhibitors. Novel experimental therapies, including endothelin receptor antagonists, glucagon-like peptide-1 receptor agonists, microRNA-targeted treatments, and gene or stem cell-based strategies, aim to address underlying molecular mechanism, though long-term safety and efficacy require further investigation. Advances in understanding genotype-phenotype correlations, combined with improvements in diagnostic workflows and therapeutic modalities, provide opportunities to slow disease progression, optimize clinical outcomes, and improve quality of life. This review summarizes current knowledge of AS, emphasizing clinical heterogeneity, diagnostic approaches, and evolving treatment paradigms.
References
Quinlan, C., & Rheault, M. N. (2021). Genetic Basis of Type IV Collagen Disorders of the Kidney. Clinical journal of the American Society of Nephrology : CJASN, 16(7), 1101–1109. https://doi.org/10.2215/CJN.19171220
Ostrowska-Spaleniak, A., Krix-Jachym, K., & Rękas, M. (2017). Ocular manifestation and surgical treatment outcomes in Alport syndrome – case series. Klinika Oczna / Acta Ophthalmologica Polonica, 119(2), 116-119. https://doi.org/10.5114/ko.2017.71782
Kang, E., Park, B. H., Lee, H., Kang, H. G., Kim, J. H., Kim, Y. N., Jung, Y., Rim, H., & Shin, H. S. (2025). A comprehensive review of Alport syndrome: definition, pathophysiology, clinical manifestations, and diagnostic considerations. Kidney research and clinical practice, 44(4), 566–575. https://doi.org/10.23876/j.krcp.24.065
Moczulska, A., Walkosz, J., Zarębska, E., Mleczko, M., Zachwieja, K., Wierzchowska-Słowiaczek, E. ... Drożdż, D. (2017). Rozpoznanie zespołu Alporta i nefropatii cienkich błon podstawnych w wieku dziecięcym. Annales Academiae Medicae Silesiensis, 71, 73-81. https://doi.org/10.18794/aams/69243
Kashtan C. E. (2021). Alport Syndrome: Achieving Early Diagnosis and Treatment. American journal of kidney diseases : the official journal of the National Kidney Foundation, 77(2), 272–279. https://doi.org/10.1053/j.ajkd.2020.03.026
Martínez-Pulleiro, R., García-Murias, M., Fidalgo-Díaz, M., & García-González, M. Á. (2021). Molecular Basis, Diagnostic Challenges and Therapeutic Approaches of Alport Syndrome: A Primer for Clinicians. International journal of molecular sciences, 22(20), 11063. https://doi.org/10.3390/ijms222011063
Savige, J., & Harraka, P. (2021). Pathogenic Variants in the Genes Affected in Alport Syndrome (COL4A3-COL4A5) and Their Association With Other Kidney Conditions: A Review. American journal of kidney diseases : the official journal of the National Kidney Foundation, 78(6), 857–864. https://doi.org/10.1053/j.ajkd.2021.04.017
Shang, S., Peng, F., Wang, T., Wu, X., Li, P., Li, Q., & Chen, X. M. (2019). Genotype-phenotype correlation and prognostic impact in Chinese patients with Alport Syndrome. Molecular genetics & genomic medicine, 7(7), e00741. https://doi.org/10.1002/mgg3.741
Daga, S., Fallerini, C., Furini, S., Pecoraro, C., Scolari, F., Ariani, F., Bruttini, M., Mencarelli, M. A., Mari, F., Renieri, A., & Pinto, A. M. (2019). Non-collagen genes role in digenic Alport syndrome. BMC nephrology, 20(1), 70. https://doi.org/10.1186/s12882-019-1258-5
Kashtan, C. E., Ding, J., Garosi, G., Heidet, L., Massella, L., Nakanishi, K., Nozu, K., Renieri, A., Rheault, M., Wang, F., & Gross, O. (2018). Alport syndrome: a unified classification of genetic disorders of collagen IV α345: a position paper of the Alport Syndrome Classification Working Group. Kidney international, 93(5), 1045–1051. https://doi.org/10.1016/j.kint.2017.12.018
Cosgrove, D., & Liu, S. (2017). Collagen IV diseases: A focus on the glomerular basement membrane in Alport syndrome. Matrix biology : journal of the International Society for Matrix Biology, 57-58, 45–54. https://doi.org/10.1016/j.matbio.2016.08.005
Ramakrishnan, R., Shenoy, A., & Meyer, D. (2022). Ocular Manifestations and Potential Treatments of Alport Syndrome: A Systematic Review. Journal of ophthalmology, 2022, 9250367. https://doi.org/10.1155/2022/9250367
Savige, J., Huang, M., Croos Dabrera, M. S., Shukla, K., & Gibson, J. (2022). Genotype-Phenotype Correlations for Pathogenic COL4A3-COL4A5 Variants in X-Linked, Autosomal Recessive, and Autosomal Dominant Alport Syndrome. Frontiers in medicine, 9, 865034. https://doi.org/10.3389/fmed.2022.865034
Adone, A., & Anjankar, A. (2023). Alport Syndrome: A Comprehensive Review. Cureus, 15(10), e47129. https://doi.org/10.7759/cureus.47129
Puapatanakul, P., & Miner, J. H. (2024). Alport syndrome and Alport kidney diseases - elucidating the disease spectrum. Current opinion in nephrology and hypertension, 33(3), 283–290. https://doi.org/10.1097/MNH.0000000000000983
Gregorio, V., Caparali, E. B., Shojaei, A., Ricardo, S., & Barua, M. (2023). Alport Syndrome: Clinical Spectrum and Therapeutic Advances. Kidney medicine, 5(5), 100631. https://doi.org/10.1016/j.xkme.2023.100631
Martínez-Pulleiro, R., García-Murias, M., Fidalgo-Díaz, M., & García-González, M. Á. (2021). Molecular Basis, Diagnostic Challenges and Therapeutic Approaches of Alport Syndrome: A Primer for Clinicians. International journal of molecular sciences, 22(20), 11063. https://doi.org/10.3390/ijms222011063
Savige, J., Ariani, F., Mari, F., Bruttini, M., Renieri, A., Gross, O., Deltas, C., Flinter, F., Ding, J., Gale, D. P., Nagel, M., Yau, M., Shagam, L., Torra, R., Ars, E., Hoefele, J., Garosi, G., & Storey, H. (2019). Expert consensus guidelines for the genetic diagnosis of Alport syndrome. Pediatric nephrology (Berlin, Germany), 34(7), 1175–1189. https://doi.org/10.1007/s00467-018-3985-4
Gast, C., Pengelly, R. J., Lyon, M., Bunyan, D. J., Seaby, E. G., Graham, N., Venkat-Raman, G., & Ennis, S. (2016). Collagen (COL4A) mutations are the most frequent mutations underlying adult focal segmental glomerulosclerosis. Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, 31(6), 961–970. https://doi.org/10.1093/ndt/gfv325
Voskarides, K., Damianou, L., Neocleous, V., Zouvani, I., Christodoulidou, S., Hadjiconstantinou, V., Ioannou, K., Athanasiou, Y., Patsias, C., Alexopoulos, E., Pierides, A., Kyriacou, K., & Deltas, C. (2007). COL4A3/COL4A4 mutations producing focal segmental glomerulosclerosis and renal failure in thin basement membrane nephropathy. Journal of the American Society of Nephrology : JASN, 18(11), 3004–3016. https://doi.org/10.1681/ASN.2007040444
Savige, J., Rana, K., Tonna, S., Buzza, M., Dagher, H., & Wang, Y. Y. (2003). Thin basement membrane nephropathy. Kidney international, 64(4), 1169–1178. https://doi.org/10.1046/j.1523-1755.2003.00234.x
Kashtan, C. E., & Gross, O. (2021). Clinical practice recommendations for the diagnosis and management of Alport syndrome in children, adolescents, and young adults-an update for 2020. Pediatric nephrology (Berlin, Germany), 36(3), 711–719. https://doi.org/10.1007/s00467-020-04819-6
Fallerini, C., Dosa, L., Tita, R., Del Prete, D., Feriozzi, S., Gai, G., Clementi, M., La Manna, A., Miglietti, N., Mancini, R., Mandrile, G., Ghiggeri, G. M., Piaggio, G., Brancati, F., Diano, L., Frate, E., Pinciaroli, A. R., Giani, M., Castorina, P., Bresin, E., … Ariani, F. (2014). Unbiased next generation sequencing analysis confirms the existence of autosomal dominant Alport syndrome in a relevant fraction of cases. Clinical genetics, 86(3), 252–257. https://doi.org/10.1111/cge.12258
Morinière, V., Dahan, K., Hilbert, P., Lison, M., Lebbah, S., Topa, A., Bole-Feysot, C., Pruvost, S., Nitschke, P., Plaisier, E., Knebelmann, B., Macher, M. A., Noel, L. H., Gubler, M. C., Antignac, C., & Heidet, L. (2014). Improving mutation screening in familial hematuric nephropathies through next generation sequencing. Journal of the American Society of Nephrology : JASN, 25(12), 2740–2751. https://doi.org/10.1681/ASN.2013080912
Kashtan, C. E., Ding, J., Gregory, M., Gross, O., Heidet, L., Knebelmann, B., Rheault, M., Licht, C., & Alport Syndrome Research Collaborative (2013). Clinical practice recommendations for the treatment of Alport syndrome: a statement of the Alport Syndrome Research Collaborative. Pediatric nephrology (Berlin, Germany), 28(1), 5–11. https://doi.org/10.1007/s00467-012-2138-4
Huang, H. X., Tsai, I. J., & Greenbaum, L. A. (2025). Alport syndrome: Expanding diagnosis and treatment. Pediatrics and neonatology, 66 Suppl 1, S13–S17. https://doi.org/10.1016/j.pedneo.2024.10.005
Boeckhaus, J., Gale, D. P., Simon, J., Ding, J., Zhang, Y., Bergmann, C., Turner, A. N., Hall, M., Sayer, J. A., Srivastava, S., Kang, H. G., Cerkauskaite-Kerpauskiene, A., Gillion, V., Claes, K. J., Krueger, B., de Fallois, J., Walden, U., Choi, M., Schueler, M., Mueller, R. U., … Gross, O. (2024). SGLT2-Inhibition in Patients With Alport Syndrome. Kidney international reports, 9(12), 3490–3500. https://doi.org/10.1016/j.ekir.2024.09.014
Reiterová, J., & Tesař, V. (2023). Current and Future Therapeutical Options in Alport Syndrome. International journal of molecular sciences, 24(6), 5522. https://doi.org/10.3390/ijms24065522
Chavez, E., Rodriguez, J., Drexler, Y., & Fornoni, A. (2022). Novel Therapies for Alport Syndrome. Frontiers in medicine, 9, 848389. https://doi.org/10.3389/fmed.2022.848389
Chertow, G. M., Appel, G. B., Andreoli, S., Bangalore, S., Block, G. A., Chapman, A. B., Chin, M. P., Gibson, K. L., Goldsberry, A., Iijima, K., Inker, L. A., Knebelmann, B., Mariani, L. H., Meyer, C. J., Nozu, K., O'Grady, M., Silva, A. L., Stenvinkel, P., Torra, R., Warady, B. A., … Pergola, P. E. (2021). Study Design and Baseline Characteristics of the CARDINAL Trial: A Phase 3 Study of Bardoxolone Methyl in Patients with Alport Syndrome. American journal of nephrology, 52(3), 180–189. https://doi.org/10.1159/000513777
Warady, B. A., Pergola, P. E., Agarwal, R., Andreoli, S., Appel, G. B., Bangalore, S., Block, G. A., Chapman, A. B., Chin, M. P., Gibson, K. L., Goldsberry, A., Iijima, K., Inker, L. A., Kashtan, C. E., Knebelmann, B., Mariani, L. H., Meyer, C. J., Nozu, K., O'Grady, M., Rheault, M. N., … Chertow, G. M. (2022). Effects of Bardoxolone Methyl in Alport Syndrome. Clinical journal of the American Society of Nephrology : CJASN, 17(12), 1763–1774. https://doi.org/10.2215/CJN.02400222
Heerspink, H. J. L., Parving, H. H., Andress, D. L., Bakris, G., Correa-Rotter, R., Hou, F. F., Kitzman, D. W., Kohan, D., Makino, H., McMurray, J. J. V., Melnick, J. Z., Miller, M. G., Pergola, P. E., Perkovic, V., Tobe, S., Yi, T., Wigderson, M., de Zeeuw, D., & SONAR Committees and Investigators (2019). Atrasentan and renal events in patients with type 2 diabetes and chronic kidney disease (SONAR): a double-blind, randomised, placebo-controlled trial. Lancet (London, England), 393(10184), 1937–1947. https://doi.org/10.1016/S0140-6736(19)30772-X
Boeckhaus, J., Mabillard, H., & Sayer, J. A. (2025). GLP-1 receptor agonists-another promising therapy for Alport syndrome?. Journal of rare diseases (Berlin, Germany), 4(1), 5. https://doi.org/10.1007/s44162-024-00065-8
Torra, R., & Furlano, M. (2019). New therapeutic options for Alport syndrome. Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, 34(8), 1272–1279. https://doi.org/10.1093/ndt/gfz131
Rubel, D., Stock, J., Ciner, A., Hiller, H., Girgert, R., Müller, G. A., & Gross, O. (2014). Antifibrotic, nephroprotective effects of paricalcitol versus calcitriol on top of ACE-inhibitor therapy in the COL4A3 knockout mouse model for progressive renal fibrosis. Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, 29(5), 1012–1019. https://doi.org/10.1093/ndt/gft434
Lin, X., Suh, J. H., Go, G., & Miner, J. H. (2014). Feasibility of repairing glomerular basement membrane defects in Alport syndrome. Journal of the American Society of Nephrology : JASN, 25(4), 687–692. https://doi.org/10.1681/ASN.2013070798
Kuebler, B., Aran, B., Miquel-Serra, L., Muñoz, Y., Ars, E., Bullich, G., Furlano, M., Torra, R., Marti, M., Veiga, A., & Raya, A. (2017). Integration-free induced pluripotent stem cells derived from a patient with autosomal recessive Alport syndrome (ARAS). Stem cell research, 25, 1–5. https://doi.org/10.1016/j.scr.2017.08.021
Kuebler, B., Aran, B., Miquel-Serra, L., Muñoz, Y., Ars, E., Bullich, G., Furlano, M., Torra, R., Marti, M., Veiga, A., & Raya, A. (2017). Generation of integration-free induced pluripotent stem cell lines derived from two patients with X-linked Alport syndrome (XLAS). Stem cell research, 25, 291–295. https://doi.org/10.1016/j.scr.2017.08.019
Daga, S., Donati, F., Capitani, K., Croci, S., Tita, R., Giliberti, A., Valentino, F., Benetti, E., Fallerini, C., Niccheri, F., Baldassarri, M., Mencarelli, M. A., Frullanti, E., Furini, S., Conticello, S. G., Renieri, A., & Pinto, A. M. (2020). New frontiers to cure Alport syndrome: COL4A3 and COL4A5 gene editing in podocyte-lineage cells. European journal of human genetics : EJHG, 28(4), 480–490. https://doi.org/10.1038/s41431-019-0537-8
Lin, X., Suh, J. H., Go, G., & Miner, J. H. (2014). Feasibility of repairing glomerular basement membrane defects in Alport syndrome. Journal of the American Society of Nephrology : JASN, 25(4), 687–692. https://doi.org/10.1681/ASN.2013070798
Views:
30
Downloads:
24
Copyright (c) 2025 Karolina Krowiak, Anita Krowiak, Anita Warzocha, Piotr Pitrus, Karol Bednarz, Maria Jasiewicz, Gabriela Majka, Magdalena Kowalczyk, Wiktoria Hander, Aleksandra Karnas
This work is licensed under a Creative Commons Attribution 4.0 International License.
All articles are published in open-access and licensed under a Creative Commons Attribution 4.0 International License (CC BY 4.0). Hence, authors retain copyright to the content of the articles.
CC BY 4.0 License allows content to be copied, adapted, displayed, distributed, re-published or otherwise re-used for any purpose including for adaptation and commercial use provided the content is attributed.
